Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294887 | 0.87 | GRIN2B (0.39) | DRD2GRIN2BOPRL1DRD4HTR1A | |
| SCHEMBL17294892 | 0.82 | RORC (0.40) | MEN1KMT2A | |
| SCHEMBL18590786 | 0.76 | OPRL1 (0.35) | GRIN2BOPRL1POLB | |
| SCHEMBL30694037 | 0.73 | POLB (0.38) | POLB | |
| SCHEMBL23706089 | 0.71 | ALDH1A1 (0.50) | DRD2ALDH1A1OPRL1PRMT5WDR77 | |
| SCHEMBL2971442 | 0.71 | GRIN2B (0.40) | DRD2GRIN2BOPRL1DRD4HTR1A | |
| SCHEMBL1669519 | 0.70 | GRIN2B (0.44) | DRD2GRIN2BALDH1A1OPRL1POLB | |
| SCHEMBL17294859 | 0.70 | GRIN2B (0.43) | GRIN2BOPRL1 | |
| SCHEMBL17294879 | 0.70 | GRIN2B (0.43) | GRIN2BOPRL1 | |
| SCHEMBL25366430 | 0.69 | DRD2 (0.39) | DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149002-B1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9663530-B2 | 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3149002-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2015181061-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | GRIN2C, NR3C2, HTR2C | DRD2 107/4885GRIN2B 11/4885ALDH1A1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.